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Abstract
Successful immune-mediated regression of solid tumors is difficult because of the small number of cytotoxic T lymphocytes
(CTLs) that were traffic to the tumor site. Here, the targeting of tumor-specific infiltrating CTLs was dependent on a fusion
protein consisting of human epidermal growth factor (EGF) and staphylococcal enterotoxin A (SEA) with the D227A
mutation. EGF-SEA strongly restrained the growth of murine solid sarcoma 180 (S180) tumors (control versus EGF-SEA, mean
tumor weight: 1.013 versus 0.197 g, difference =0.816 g). In mice treated with EGF-SEA, CD4
+, CD8
+ and SEA-reactive T
lymphocytes were enriched around the EGFR expressing tumor cells. The EGF receptors were potentially phosphorylated by
EGF-SEA stimulation and the fusion protein promoted T cells to release the tumoricidal cytokines interferon-c (IFN-c) and
tumor necrosis factor-a (TNF-a). Intratumoral CTLs secreted cytolytic pore-forming perforins and granzyme B proteins near
the surface of carcinomas, causing the death of many tumor cells. We additionally show that labeled EGF-SEA was directly
targeted to the tumor tissue after intravenous (i.v.) injection. The findings demonstrate that antibody-like EGF-SEA plays an
important role in arresting CTLs in the solid tumor site and has therapeutic potential as a tumor-targeting agent.
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Introduction
The major lymphocytes in the blood are T cells. Usually, the T
cell receptors (TCRs) of T cells cannot recognize self antigens on
the surface of cancer cells. Thus, T cells moving through solid
tumors in blood vessels are not reactive to cancer-associated
antigens. The induction of tumor-reactive T cells has been
attempted by various strategies, such as the use of CD3-based
bispecific antibodies [1–3], and antibodies conjugated with a
superantigen such staphylococcal enterotoxin A (SEA) [4–6].
However, the question of how to recruit large pools of effector T
lymphocytes to solid tumors in order to facilitate tumor infiltration
is still an attractive challenge. The mechanisms underlying tumor
eradication that depend on the infiltration of cytotoxic T
lymphocytes (CTLs) to solid tumors remain largely unknown.
The movement of antibodies after intravenous (i.v.) injection has
not been clearly shown. Thus, it is an open question as to whether
only the tumor is targeted by the antibodies or whether other
organs would retain them as well.
We developed a novel antibody-like fusion protein composed of
human epidermal growth factor (EGF) and staphylococcal
enterotoxin A (SEA) and examined its targeting to tumors and
the tumoricidal immunostimulatory responses. The EGF receptor
(EGFR) is an attractive target for therapy because EGFRs are
often overexpressed in carcinomas [7]. Thus a cytotoxic agent that
binds this receptor may have therapeutic applications. EGF and
diphtheria toxin fusion proteins have been evaluated for their
ability to induce regressions of subcutaneous human glioblastomas
in athymic nude mice [8]. Additionally, EGF hybrids carrying
pseudomonas exotoxin or ribonuclease displayed selective cyto-
toxicity against tumor cells bearing elevated EGFRs [9,10]. These
chimeric EGF proteins functioned as tumor-targeting molecules,
but they were not dependent on antitumor immunocytotoxicity.
SEA can activate a large number of T cells carrying a particular
TCR variable b chain [11] and induce a strong cytokine
production and CTLs in the CD4
+ and CD8
+ groups [4,5].
The SEA gene employed in this study carried the D227A
mutation. This mutant created by Dohlsten’s group displayed a
1,000-fold reduction in major histocompatibility complex class
(MHC) II binding to reduce systemic toxicity [6] and was
consequently conjugated with antibodies as a powerful CTL
inducer against cancer [6,12,13]. These fusion protein or
antibodies fused with unmutant SEA [4,5,14,15] inhibited blood
carcinomas and metastases. Here by using fusion with EGF to
target SEA (D227A) to the solid tumor, it becomes possible to
retain tumor-unspecific T lymphocytes in the tumor site.
Materials and Methods
Protein preparation
A synthetic DNA fragment (Takara, Dalian, China) encoding a
short linker peptide VDKLGGGGSGGGGSGGGGS, and the
SEA gene encoding 233 amino acids [16] with the D227A
mutation [6] were integrated into a modified pET22b (containing
E-tag sequence GAPVPYPDPLEPR between the Not I and Xho I
sites from pCANTAB 5E of the antibody phage display system,
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and Not I sites to produce SEA. Another synthetic human EGF
DNA fragment (Takara, Dalian, China) encoding 53 amino acids
[17] was inserted at the EcoR I and Hind III sites of pET22b-SEA
to produce the fusion protein EGF-SEA. The molecular weights of
SEA and EGF-SEA including the leader and upstream sequences
in pET22b were estimated as 34.6 and 41.2 kDa, respectively.
Two proteins, which expressed as inclusion bodies in Escherichia coli
L21(DE3) strain, were purified using immobilized metal ion (Ni
2+)
affinity chromatography, refolded using to the method of GSSG
and arginine dialysis [18], and resolved by 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
Murine tumor model
Male ICR mice (Experimental Animal Center, Academy of
Military Medical Sciences, Beijing, China), 4–5 weeks old and 18–
22 g, were employed in the tumor model. All mice were
maintained in a specific pathogen free (SPF) facility at Tianjin
University of Science & Technology. The animal experiments
were approved by the Institutional Biosafety Committee and the
Animal Care according to the guideline on animal research
(No. 503012) and Use Committee of Tianjin University of Science
& Technology with a permit number of TUST070824. Mouse
sarcoma 180 (S180) cells were from the American Type Culture
Collection (Manassas, VA). Each mouse was subcutaneously
inoculated with 2610
6 S180 cells suspended in phosphate-buffered
saline (PBS) into the right axilla. Mice were divided into three
groups (n=15 per group) and given two daily intraperitoneal (i.p.)
injections (0.2 ml) with 0.9% NaCl saline (control), SEA
(250 pmol) and EGF-SEA (250 pmol), starting on day 2 after
tumor inoculation. The tumors were measured on day 9.
Fluorescent labeling of EGF-SEA
Purified EGF-SEA proteins were labeled with Kodak X-SIGHT
670 TFP ester (Carestream Health, Rochester, NY, USA)
according to the protocol (Carestream Molecular Imaging).
Briefly, dyes were conjugated with proteins in a sodium phosphate
buffer (100 mM, 0.15 M NaCl, pH 7.2) and unconjugated dyes
were neutralized by ammonium chloride. The labeled proteins
were purified from free dyes on a Sephadex G-25 column. The
ratio of free dyes to the proteins (degree of labeling) was estimated
by measuring absorbance at 280 nm and 670 nm.
Flow cytometry
S180 cells were collected, centrifuged at 1,500 rpm, and re-
suspended in PBS. Aliquots of 2610
6 cells were incubated with
125.00, 12.50 and 1.25 pmol of LSS670-labeled EGF-SEA
proteins, respectively, at 4uC for 30 min, and washed in cold
PBS. The ability of labeled-EGF-SEA to bind to S180 cells was
quantified by fluorescence-activated cell sorter (FACS) analyses
using a BD FACS Calibur (Becton Dickinson Medical Devices,
Franklin Lakes, NJ, USA).
Immunohistochemistry
Tissues from 8 mice per group were fixed in 4% phosphate-
buffered formalin, embedded in paraffin, sectioned at 5 mm,
deparaffinized in xylene and then rehydrated in graded ethanol
using a general method. Sections were incubated first in a 3%
hydrogen peroxide solution to block endogenous peroxidases, then
with a protein-blocking solution containing preimmune rabbit
serum, and finally with the following primary antibodies (1:250
dilution in PBS containing 1% bovine serum albumin) in each test:
rabbit CD4-specific polyclonal antibody, rabbit CD8-specific
polyclonal antibody, rabbit interferon-c (IFN-c)-specific polyclonal
antibody, rabbit tumor necrosis factor-a (TNF-a)-specific poly-
clonal antibody, rabbit Fas-specific polyclonal antibody, and
rabbit perforin-specific polyclonal antibody from Santa Cruz
Biotechnology (Cruz, CA, USA); mouse phospho-EGFR-specific
monoclonal antibody (Y 1068) from Cell Signaling Technology
(Danvers, MA, USA); rabbit granzyme B-specific polyclonal
antibody from Abcam (Cambridge, MA, USA); goat anti-mouse
or anti-rabbit secondary antibody from Invitrogen (Carlsbad, CA,
USA). To prepare SEA-specific antibodies, SEA purified from the
recombinant E. coli was raised in BALB/c mice, and the IgG
fraction from the antiserum with a titer over 8000 was purified
using a Hitrap Protein G-Sepharose column (GE Healthcare Life
Sciences, Piscataway, NJ, USA). Antibody-binding was detected
by incubation with the secondary antibody for 1 hr, and then
avidin-biotin-peroxidase complex (Zymed, San Francisco, CA,
USA) for 30 min followed by diaminobenzidine (DAB) for 8 min.
The slides were rinsed with PBS and counterstained with
hematoxylin for 1 min. About 15–20 sections were analyzed for
each antibody assay, and sections detected for T cells, cytokines,
Fas and granulolytic proteins were from the same tumor.
Cytokine release
Blood and spleen samples were collected after the mice were
dissected. All groups contained pooled sera and spleens from at
least three mice. Protein levels of TNF-a and IFN-c were
measured using specific enzyme-linked immunosorbent assay
(ELISA) kits (R & D Systems, Minneapolis, MN, USA) according
to instructions from the manufacturer.
TUNEL staining
To assess fragmented DNA, sections were labeled by the
terminal deoxynucleotidyl transferase biotin-dUTP nick-end
labeling (TUNEL) technique using an In Situ Cell Death
Detection Kit (Roche Applied Science, Mannheim, Germany).
Additional sections were incubated with terminal deoxynucleotidyl
transferase (TdT), a fluorescein-labeled nucleotide mixture, in a
wet chamber at 37uC for 1 hr. The sections were then washed
with PBS and incubated with anti-fluorescein antibody conjugated
with horseradish peroxidase (POD) for 30 min.
Imaging of mice
EGF-SEA proteins (125 pmol) labeled by LSS670 were injected
i.v. via the tail vein into mice bearing tumors of 0.5,1.0 cm in
diameters or into mice that had not been inoculated with S180
cells. Mice were anesthetized and the targeting of labeled proteins
to tumors was monitored for 62 hrs using in vivo fluorescence
imaging IVIS Kinetic (Caliper Life Sciences, Hopkinton, MA,
USA) with an excitation bandpass filter at 710 nm and collecting
emissions from 810 to 885 nm.
Results
Inhibition of the growth of solid murine S180 tumors
Human EGF and SEA gene fragments were subcloned into
pET22b and expressed in E. coli. EGF-SEA and SEA products
were then purified and refolded. The proteins secreted into the
periplasmic space of E. coli were not detected. The molecular
weights of SEA and EGF-SEA were close to 35 kDa and over
40 kDa, respectively (Figure 1A) and the trace of the proteins
below two major bands of the proteins may be cleavaged by a
signal peptidase, whereas the major proteins formed as inclusion
bodies may be not processed. The refolded proteins were utilized
in animal tumor model.
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cells were subcutaneously inoculated into the right axilla of ICR
mice, followed by i.p. injections of saline (control), SEA, or EGF-
SEA, respectively. The solid tumors appeared on day 5 and
quickly expanded over the next 2 days in the control mice, while
the growth of tumors was delayed in mice treated with EGF-SEA
Figure 1. Inhibition of S180 tumor growth. (A) SDS-PAGE identification of proteins. Lane 1, SEA; lane 2, EGF-SEA. (B) Effect of treatments on the
growth of S180 tumors. After mice were inoculated with 2610
6 S180 cells into the right axilla, they were treated with two daily i.p. injections (0.2 ml)
of 0.9% NaCl saline (control), SEA (250 pmol) and EGF-SEA (250 pmol) starting 1 day after tumor inoculation. n=15 mice per group. *p,0.001. (C)
Inhibition of S180 tumors. Mice were dissected and the tumors were measured on day 9. Yellow arrows indicated the tumor position. *p,0.001. (D)
Effect of treatments on spleens.
doi:10.1371/journal.pone.0016642.g001
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a 1–2 day delay compared to the control mice. EGF-SEA strongly
suppressed solid tumor growth (control versus EGF-SEA, mean
tumor weight: 1.013 versus 0.197 g, difference =0.816 g, 95%
confidence interval [CI] =0.54 to 1.37, p,0.001) (Figure 1C),
and had a slight influence on the spleen measured by weight
(Figure 1D). The control/EGF-SEA tumor weight ratio was 5.14.
Interaction between EGF-SEA proteins and S180 cells
Immunohistochemistry performed after incubation of tumor
sections with an EGF-SEA solution and detection by anti-SEA
IgG demonstrated that large tumor cells and T cells (small spots) in
tumors were associated with EGF-SEA proteins (Figure 2A),
whereas no positive cells were detected in a section treated only
with the anti-mouse secondary antibody (Figure 2C). Because of
EGF-SEA containing an E-tag peptide, positive tumor cells and T
cells were also found using anti-E-tag IgG detection (data not
shown).
The phosphorylation of EGFR at Tyr-1068 occurred in many
S180 cells of the EGF-SEA treated group, but was low and
negligible in the SEA and control groups, respectively (Figure 2B).
In a control of the immunohistochemistry, no labeling was
observed in a tumor treated with EGF-SEA using only the goat
anti-mouse secondary antibody (Figure 2C).
The ability of EGF-SEA to bind to S180 cells was directly
demonstrated using FACS analysis. Nearly 95% of the S180 cells
(2610
6) were coated with LSS670-labeled EGF-SEA molecules
after incubation with 125 pmol of EGF-SEA proteins (Figure 2D).
S180 cells bound labeled EGF-SEA proteins decreased with
reduction in the protein concentration.
CD4
+, CD8
+ and SEA-reactive T cells and cytokine
secretions
Infiltrating T lymphocytes were detected in S180 tumors treated
with EGF-SEA and found to be CD4
+, CD8
+ and SEA-reactive
(Figure 3). Large positive spots judged to be S180 cells reflected
that abundant T cells were presented on the surface of tumor cells.
The number of SEA-reactive T cells seemed to be close to or over
the sum of CD4
+ and CD8
+ T cells. Only few and negligible T
cells were detected in the tumors of SEA and control groups,
respectively.
In tumors treated with EGF-SEA, there was a large increase in
secretion of TNF-a and IFN-c around the S180 cells (Figure 4A
and B), whereas the levels of the blood and spleen were relatively
low (Figure 4C). In contrast, high levels of cytokines were found in
blood and spleen of mice treated with SEA.
Apoptosis of tumor cells
In addition to this local increase in cytokine secretion in treated
tumor, immunohistochemistry analysis showed that Fas expression
was upregulated and largely restricted in the tumors treated with
EGF-SEA (Figure 5A). Activated T cells secreted pore-forming
perforins onto the target and lytic granzyme B granules
concentrated on the membrane of S180 cells (Figure 5B and C).
As according to a perforin report [19], the molecules assembled a
strip were judged to be perforin. Through the direct killing
mediated by perforins and granzyme granules acting together with
the apoptotic inducers, TNF-a and Fas (Figure 5A), tumor cells
were eliminated in EGF-SEA-treated mice, as demonstrated by
TUNEL staining (Figure 5D).
In vivo imaging of EGF-SEA targeting to solid tumors
To avoid dye-labeling background and show a clear route of
EGF-SEA movement in mice, LSS670-labeled EGF-SEA was
injected i.v. via the tail vein. In the initial 8 hrs after the injection,
the protein stayed in the tails of mice (Figure 6). The protein then
diffused to the abdomen and bosom over a course of 18 to 54 hrs,
reaching the tumors 18 hrs after the injection. The bladder stored
excretive proteins with the peak retention occurring from 26 to
36 hrs and then gradually decreasing after 44 hrs. Finally,
abundant proteins accumulated in the tumor tissue, but there
was negligible deposition in other organs except bladder
containing the remaining traces of the unexcreted proteins. In a
mouse that had not been inoculated with S180 carcinomas,
labeled protein was largely removed via bladder from the body,
although there was random diffusion of the protein.
Discussion
Enhanced EGFR expression has been found in a wide variety of
malignancies, including esophageal, lung, thyroid, gastric, bladder,
renal, prostate, ovarian, endometrial and breast. One mucinous
adenocarcinoma was shown to have an extreme elevation in levels
of EGF receptors, corresponding to a 320-fold increase over
normal mucosa [7]. The amount of EGFR expressed on S180 cells
is likely to be abundant as a large amount of the EGF-SEA protein
accumulated in the tumor site, peaking 62 hrs after i.v. injection
(Figure 6). In contrast, the protein did not persist in other organs
except the bladder containing traces of excreted or degraded EGF-
SEA proteins, indicating that only the tumor had highly affinity for
EGF-SEA and acted as a reservoir in which EGF-SEA molecules
flowing through blood vessels were stored.
Although there are cross-interactions between EGF family and
their receptors from human and mouse based on the structural
similarity [17,20], such as human EGF binding the mouse EGF
receptor [21] and mouse EGF binding the human EGF receptor
[22], we confirmed that the human EGF peptide of the EGF-SEA
fusion protein bound the EGFR of S180 cells by showing the
interaction of anti-SEA antibody with EGFR-interacting EGF-
SEA molecules (Figure 2A) and performing FACS analysis
(Figure 2D). Moreover, labeling with a phospho-specific antibody
showed that EGF-SEA probably caused EGFR phosphorylation at
Tyr-1068 (Figure 2B).
The first injection of EGF-SEA solution was performed 2 days
after inoculation of mice with S180 cells and the EGF-SEA protein
reached the colonial S180 carcinomas 18 hrs later (Figure 6).
Thus, there were 18 hrs for S180 cells to develop into a growing
tumor before the arrival of EGF-SEA. Once the tumor formed a
site for the retention of EGF-SEA proteins, it was possible for
Figure 2. Interactions between EGF-SEA and EGFRs expressed by S180 carcinomas. (A) EGF-reactive S180 tumor cells and SEA-reactive T
cells. Sections were incubated with an EGF-SEA solution, followed by mouse polyclonal anti-SEA IgG fraction and anti-mouse secondary antibody.
Anti-SEA antibodies were able to react with EGF-SEA on the surface of S180 tumor cells and T lymphocytes (small brown spots in the section treated
with EGF-SEA). (B) Detection of phospho-EGFR (Y 1068) in S180 cells. Sections were labeled with mouse phospho-EGFR-specific monoclonal antibody
(Y 1068). Phosphorylated EGFR molecules were found in the tumors treated with EGF-SEA and SEA (red arrows). (C) An immunohistochemistry
control. A tumor section from the EGF-SEA treated group was labeled with goat anti-mouse secondary antibody only. (D) Analysis of LSS670-labeled
EGF-SEA binding to S180 cells by FACS analysis. S180 cells (2610
6) were incubated with 125.00, 12.50 and 1.25 pmol of LSS670-labeled EGF-SEA
proteins and PBS (control). Microscope magnification: 6400 in A to C.
doi:10.1371/journal.pone.0016642.g002
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+ and CD8
+ T
cells to be likewise retained. More carcinoma-associated EGF-SEA
molecules resulted in more captured T cells neighboring to or
anchored on the surface of S180 tumor cells. After accumulation,
the T cells stimulated by EGF-SEA became tumor-sensitive CTLs
that secreted the tumoricidal cytokines TNF-a and IFN-c
(Figure 4), and the granulolytic proteins perforins and granzyme
B (Figure 5). Additionally, tumor cells were found to have
increased expression of Fas, which might be up-regulated by IFN-
c and TNF-a [23–25]. Perforin is a granule protein capable of
forming transmembrane pores that are able to play as passive
directors of granzymes into the target cell membrane and also
Figure 3. Detection of intratumoral CTLs. Small brown spots around S180 tumor cells indicated antibody-reactive T cells. (A) CD4-positive cells
detected by rabbit CD4-specific polyclonal antibody. (B) CD8 positive cells detected by rabbit CD8-specific polyclonal antibody. (C) SEA-reactiveT
cells. Sections were incubated with a SEA solution, followed by mouse polyclonal anti-SEA IgG fraction and anti-mouse secondary antibody.
Microscope magnification: 6400 in A to C.
doi:10.1371/journal.pone.0016642.g003
Tumor-Targeting Cytotoxic T Lymphocytes
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16642allow an ionic exchange that causes osmotic imbalance and in
consequence, cell death [26,27]. Granzymes are released as a
multi-molecular complex, inducing apoptosis by caspase-indepen-
dent or –dependent pathways [28,29].
Increasing the intratumoral concentration of cytokines such as
IFN-c and TNF-a [30,31] would directly enhance the cytotoxic
immune responses against tumors while causing only limited
systemic toxicity. In contrast, treatment with a non-specific SEA
would irritate T lymphocytes in the whole body. In SEA-injected
controls, some percentageof the T cellsrecirculated to thespleen,as
shown by their distinct incidence on the spleen (Figure 1D) and
increased cytokine levels in the spleen and blood (Figure 4C). There
was also lower cytokine production in the tumors, as reflected by the
detection of fewer T cells (Figure 3). Cytokine secretion seemed to
Figure 4. Cytokine release in mice bearing S180 tumors. (A) TNF-a secretion in tumors. The sections were labeled with rabbit TNF-a-specific
polyclonal antibody. (B) IFN-c secretion in tumors. The sections were labeled with rabbit IFN-c-specific polyclonal antibody. (C) Cytokine secretion in
mice. The data represented cytokine levels in sera in pg/ml and in spleens in pg/g. Cytokines in blood and spleen samples were measured using
specific ELISA kits. Microscope magnification: 6400 in A and B.
doi:10.1371/journal.pone.0016642.g004
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adhered and proliferated, demonstrating that the targeting of
tumor-infiltrating CTLs by EGF-SEA was required for the
restriction of cytokine cytotoxicity to the tumor site.
A question remains as to whether localization of lymphocytes to
a tumor requires specific recognition of a tumor antigen in the
vascular compartment or whether the initial recruitment is
dependent on the characteristics of the tumor-associated vascula-
Figure 5. Apoptosis of S180 carcinomas. (A) Detection of Fas expression in S180 tumor cells using rabbit Fas-specific polyclonal antibody. Fas
molecules were detected on the surface of S180 cells (brown staining). (B) Perforin secretion by T cells in S180 tumors. Perforins were detected by
rabbit perforin-specific polyclonal antibody, and found to be pore-forming (red arrows). (C) Secretion of granzyme B by T cells in S180 tumors.
Granzyme B proteins were detected by rabbit granzyme B-specific polyclonal antibody. (D) Cell death in S180 carcinomas. Apoptotic tumor cells were
detected by TUNEL staining. Microscope magnification: 6400 in A to D.
doi:10.1371/journal.pone.0016642.g005
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recruitment of antitumor effector cells remains unclear. However,
the ability of the leukocyte population to identify tumor-associated
antigens and kill the cells that express them is not sufficient to
affect a complete antitumor response in animal models. A possible
explanation for this could be deficient homing of cells with
necessary specificity to the tumor site [32].
Targeting CTLs to the site of tumors in animal models is a
labor-intensive process. However, it is of great potential thera-
peutic interest because the frequency of tumor-specific effector T
lymphocytes is generally insufficient to arrest progressive tumor
growth. The majority of T cells are trapped in the liver, spleen or
lungs, generating in low assembly of tumor-sensitive T lympho-
cytes in the tumor tissue [32–35].
In mice treated with saline or SEA, T lymphocytes without the
specificity for tumor-associated antigens did not stop moving or
eliminate tumor cells (Figure 5D), resulting in a lack of adequately
intratumoral CTLs (Figure 3). The success of immunotherapeutic
strategies against cancer depends on the generation of effective
tumor-specific T lymphocytes that must not only enter the tumor
area but also can traverse the interstitial region and directly
interact with the target cells [36].
In the present work, S180 cells were inoculated into the right
axilla of mice to induce solid tumor formation. After one day of
colonization, EGF-SEA was administered by i.p. injections.
Following a period of random diffusion, EGF-SEA molecules
selectively concentrated in developing tumors that expressed
sufficient EGFR, and then retained the passage of T lymphocytes
within the tumor site. This retention of T cells effected their deep
infiltration into solid tumors, even though the lymphocytes were
unable to recognize tumor-autologous antigens specifically. Once
EGF-SEA-promoting infiltrating CTLs accumulated in the tumor
site, the tumor became apoptotic by an in situ attack. EGF-SEA
thus established a bridge between CTLs and tumors, in which
EGF targeted the fusion protein to tumors expressing abundant
EGF receptors and SEA provoked the infiltrating CTLs into lysing
solid tumors by granule exocytosis and a Fas-mediated death
pathway. These findings suggest that close-contact accumulation
of CTLs within the tumor site is required for effective tumor
suppression.
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